Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sickle Cell Anemia: early-phase trial registry
6 of 23 indexed Sickle Cell Anemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 6 currently recruiting · #724 of 28,707 conditions by registered trial count
Sickle Cell Anemia: 23 US clinical trials tracked, 6 recruiting.
Sickle Cell Anemia is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 5 of these trials.
Enrollment posture brief
Registry condition sickle-cell-anemia
OPEN 6 | RECR 26% | LATE 1 | EARLY 10 | RANK #724 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Parkinson's Disease (26% recruiting · 161 trials)
Sickle Cell Anemia lists 6 open slots (26% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sickle Cell Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sickle Cell Anemia is recruiting below its size-band peers.
6 of 23 indexed trials (26.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Sickle Cell Anemia research.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 5 of 23 trials (21.7%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Sickle Cell Anemia trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 23 trials that report a genuine target (sentinel values excluded). 15 of those (65.2%) plan for fewer than 100 participants.
-
Sickle Cell Anemia splits between interventional and observational designs.
14 interventional and 9 observational studies make up this index (60.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
Blood Sampling for Research Related to Sickle Cell Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00542230
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
Children's Hospital Medical Center, Cincinnati
NCT04093986
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
NCT07356050
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
University of California, Davis
NCT06016634
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
NCT05477563
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Paul Szabolcs
NCT03653338
Stroke Prevention in Young Adults With Sickle Cell Anemia
Vanderbilt University Medical Center
NCT04808778
Sickle Cell Disease (SCD) Bone Pain Study
University of California, Davis
NCT05283148
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
National Heart, Lung, and Blood Institute (NHLBI)
NCT05357482
Haploidentical PBMC Transplant for Severe Congenital Anemias
National Heart, Lung, and Blood Institute (NHLBI)
NCT00977691
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT05675436
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
Vanderbilt University Medical Center
NCT04800809
Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Sickle Cell Anemia
Namita Sood
NCT01783093
Decision Aid for Therapeutic Options In Sickle Cell Disease
Emory University
NCT02326597
Heart Disease in Sickle Cell Anemia
National Institutes of Health Clinical Center (CC)
NCT00113152
Microvascular Blood Flow in Sickle Cell Anemia
Versiti Blood Health
NCT01566890
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
Icagen
NCT00040677
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
National Heart, Lung, and Blood Institute (NHLBI)
NCT00023296
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
Pfizer
NCT04255875
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Children's Mercy Hospital Kansas City
NCT01506544
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)
NCT00495638
Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
Susan P. Perrine
NCT00004412
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Case Comprehensive Cancer Center
NCT02065596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Sickle Cell Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sickle Cell Anemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sickle Cell Anemia page
23 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Sickle Cell Anemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Sickle Cell Anemia trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sickle Cell Anemia condition card totals 23 registered trials; most-linked intervention Hydroxyurea; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.